BeOne Medicines Ltd. (ONC)
416.54
+0.58
(+0.14%)
USD |
NASDAQ |
Nov 13, 16:00
416.76
+0.22
(+0.05%)
After-Hours: 19:59
BeOne Medicines Net Income (Quarterly) : 385.73M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 385.73M |
| June 30, 2026 | 237.40M |
| March 31, 2026 | 228.03M |
| December 31, 2025 | 66.79M |
| September 30, 2025 | 125.01M |
| June 30, 2025 | 94.66M |
| March 31, 2025 | 1.27M |
| December 31, 2024 | -151.34M |
| September 30, 2024 | -121.35M |
| June 30, 2024 | -120.40M |
| March 31, 2024 | -251.15M |
| December 31, 2023 | -367.55M |
| September 30, 2023 | 215.41M |
| June 30, 2023 | -381.14M |
| March 31, 2023 | -348.43M |
| December 31, 2022 | -445.34M |
| September 30, 2022 | -557.56M |
| June 30, 2022 | -562.24M |
| March 31, 2022 | -435.80M |
| December 31, 2021 | -591.81M |
| September 30, 2021 | -438.70M |
| June 30, 2021 | -480.34M |
| March 31, 2021 | 66.50M |
| Date | Value |
|---|---|
| December 31, 2020 | -472.65M |
| September 30, 2020 | -426.62M |
| June 30, 2020 | -336.32M |
| March 31, 2020 | -364.94M |
| December 31, 2019 | -387.90M |
| September 30, 2019 | -308.66M |
| June 30, 2019 | -85.95M |
| March 31, 2019 | -168.07M |
| December 31, 2018 | -266.71M |
| September 30, 2018 | -144.49M |
| June 30, 2018 | -157.72M |
| March 31, 2018 | -105.12M |
| December 31, 2017 | -99.28M |
| September 30, 2017 | 117.28M |
| June 30, 2017 | -60.68M |
| March 31, 2017 | -50.62M |
| December 31, 2016 | -37.60M |
| September 30, 2016 | -35.49M |
| June 30, 2016 | -24.12M |
| March 31, 2016 | -22.00M |
| December 31, 2015 | -27.25M |
| September 30, 2015 | -29.85M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | -10.77M |
| CRISPR Therapeutics AG | -111.44M |
| Idorsia Ltd. | -65.28M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.895B |
| Total Expenses (Quarterly) | 1.509B |
| EPS Diluted (Quarterly) | 3.288 |
| Enterprise Value | 40.06B |
| Gross Profit Margin (Quarterly) | 86.84% |
| Profit Margin (Quarterly) | 20.36% |
| Earnings Yield | 1.89% |
| Operating Earnings Yield | 2.44% |
| Normalized Earnings Yield | 1.945 |